Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Parainfluenza Virus Infection- Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Parainfluenza Virus Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Parainfluenza Virus Infection from 2017 to 2028 segmented by G8 countries. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China
Study Period: 2017-2028
Parainfluenza Virus Infection - Disease Understanding and Treatment Algorithm
The Parainfluenza Viruses (PIVs) are non-segmented, negative-strand RNA viruses of the family Paramyxoviridae. The paramyxoviruses include not only the PIVs but also several other important human pathogens transmitted through the respiratory route such as a human respiratory syncytial virus (HRSV), metapneumovirus, measles virus, and mumps virus. The human PIVs (HPIVs) consist of four serotypes (HPIV1-4), are a common cause of upper respiratory tract (URT) infections and are a leading cause of lower respiratory tract (LRT) disease in infants and children. The HPIVs are efficiently transmitted by direct contact and exposure to nasopharyngeal secretions, and nearly all children are infected with HPIV3 by age 2 and with HPIV1 and HPIV2 by age 5. Anti-PIV vaccines or drugs are not available, and therefore, non-pharmaceutical interventions are currently the only means of control. The treatment of the Parainfluenza Virus Infection is only supportive and symptomatic. Hence, no drug is approved for the treatment of the disease, therefore, it is considered as the major issue of the disease.
The DelveInsight Parainfluenza Virus Infection market report gives the thorough understanding of the Parainfluenza Virus Infection by including details such as disease introduction, serotypes, signs and symptoms, molecular biology, pathogenesis and immunology, clinical manifestations, diagnosis and treatment.
Parainfluenza Virus Infection Epidemiology
Over the last decade, it has been found that there has been a considerable change in both the nomenclature and taxonomic relationships of human parainfluenza viruses (HPIV). HPIVs were first discovered in the late 1950s when three different viruses were recovered from children with a lower respiratory disease which proved to be unique and easily separated from the myxoviruses (influenza virus) which closely resemble the parainfluenza virus. Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Parainfluenza Virus Infection in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2017-2028 for the following aspects:
• Prevalent Population of Parainfluenza Virus Infection
• Diagnosed Prevalent Population of Parainfluenza Virus Infection
• Prevalent Population of Parainfluenza Virus Infection based on the Serotypes
• Prevalent Population of Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients
According to a study conducted by H. Kelly et al. titled “Parainfluenza Viruses” the study threw light on the number of cases that come into the picture due to parainfluenza virus infections. It was found that between 500,000 and 800,000 LRI hospitalizations (in persons younger than 18 years) in the United States each year. Looking at the aspect of admitted cases for PIV according to serotype epidemiology each HPIV-1 resulted in an estimated 18,000– 3,50,000 US children younger than 5 years. For HPIV-2 as many as around 6000 children younger than 18 years may be hospitalized each year in the United States. About 60% of all HPIV-2 infections occur in children younger than 5 years, and although the peak incidence is between 1 and 2 years of age. For HPIV-3 scenario which is the most common amongst other serotypes, it was found that young infants (younger than 6 months) are particularly vulnerable to infection. Unlike the other HPIV, approximately 40% of HPIV-3 infections are in the first year of life. Bronchiolitis and pneumonia are the most common clinical presentations with HPIV-3. It is also worth noting that approximately 18,000 infants and children are hospitalized each year in the United States because of LRI caused by HPIV-3.
An another study conducted by J. Jerome et al. titled “Epidemiological, Molecular, and Clinical Features of Enterovirus Respiratory Infections in French Children between 1999 and 2005” concluded the Positive respiratory viral findings in the nasopharyngeal samples of 11,509 consecutive children attending one of the five referent pediatric emergency departments of the region Champagne Ardenne (France) from 1999 to 2005. Out of 11,509 children, 2444 (21%) were detected as positive for respiratory viral infections. The frequency of PIV Type-3 was found to be 2.4% amongst all positive respiratory viral infections.
Parainfluenza Virus Infection Drug Chapters
This segment of the Parainfluenza Virus Infection report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Parainfluenza Virus Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Parainfluenza Virus Infection & awareness of the disease. The overall dynamics of Parainfluenza Virus Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Ansun Biopharma will significantly increase the market during the forecast period (2019-2028).
Parainfluenza Virus Infection Market Outlook
The Parainfluenza Virus Infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The treatment landscape of Human Parainfluenza Virus (HPIV) comprises of very few pharmacotherapies. Currently, there are no antiviral agents with proven efficacy for Parainfluenza Virus Infection available in the market. The treatment and management of HPIV infection in healthy children and adults is mostly symptomatic. Parainfluenza Virus Infection is a common cause of significant mortality and morbidity in lung transplant recipients as well as in hematopoietic cell transplant recipients. The usual treatment and management for Human Parainfluenza Virus (HPIV) are focused on Symptomatic treatment, including preventive strategies. The current approaches to HPIV vaccines include intranasal administration of live attenuated strains, subunit strategies using the HN and F proteins, recombinant bovine/human viruses, and strains engineered using reverse genetics. In the United States, mortality is unusual and the cost of these viruses is seen mostly in health care utilization, hospitalization, lost productivity for parents, and, perhaps, long-term respiratory tract sequel in children. Ribavirin is Pharmacological drug used for the treatment of PIV infections, which has shown promising results in animal models and children with severe combined immunodeficiency. Ribavirin is a synthetic nucleoside analog which has broad-spectrum in vitro and in vivo activity against many RNA and DNA viruses. Corticosteroids are used as the primary treatment for croup and are known to be beneficial for mild-, moderate-to-severe croup. Corticosteroids are administered orally or given intramuscularly in the form of dexamethasone or prednisolone and both have been shown to be superior to inhaled therapy with budesonide. The drugs such as acetaminophen, ibuprofen are used commonly for the treatment of symptoms associated with PIV infection such as pain and fever. Other than these several other symptomatic relief options are also available like Heliox, nebulized epinephrine, etc.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Parainfluenza Virus Infection in G8 is expected to change from 2019-2028.
Parainfluenza Virus Infection Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Parainfluenza Virus Infection such as DAS-181 (Ansun Biopharma) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Parainfluenza Virus Infection market.
Parainfluenza Virus Infection Report Insights
• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Parainfluenza Virus Infection Report Key Strengths
• 10 Year Forecast
• G8 Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Parainfluenza Virus Infection Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Parainfluenza Virus Infection market
• Organize sales and marketing efforts by identifying the best opportunities for Parainfluenza Virus Infection market
• To understand the future market competition in the Parainfluenza Virus Infection market.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Parainfluenza Virus Infection from 2017 to 2028 segmented by G8 countries. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China
Study Period: 2017-2028
Parainfluenza Virus Infection - Disease Understanding and Treatment Algorithm
The Parainfluenza Viruses (PIVs) are non-segmented, negative-strand RNA viruses of the family Paramyxoviridae. The paramyxoviruses include not only the PIVs but also several other important human pathogens transmitted through the respiratory route such as a human respiratory syncytial virus (HRSV), metapneumovirus, measles virus, and mumps virus. The human PIVs (HPIVs) consist of four serotypes (HPIV1-4), are a common cause of upper respiratory tract (URT) infections and are a leading cause of lower respiratory tract (LRT) disease in infants and children. The HPIVs are efficiently transmitted by direct contact and exposure to nasopharyngeal secretions, and nearly all children are infected with HPIV3 by age 2 and with HPIV1 and HPIV2 by age 5. Anti-PIV vaccines or drugs are not available, and therefore, non-pharmaceutical interventions are currently the only means of control. The treatment of the Parainfluenza Virus Infection is only supportive and symptomatic. Hence, no drug is approved for the treatment of the disease, therefore, it is considered as the major issue of the disease.
The DelveInsight Parainfluenza Virus Infection market report gives the thorough understanding of the Parainfluenza Virus Infection by including details such as disease introduction, serotypes, signs and symptoms, molecular biology, pathogenesis and immunology, clinical manifestations, diagnosis and treatment.
Parainfluenza Virus Infection Epidemiology
Over the last decade, it has been found that there has been a considerable change in both the nomenclature and taxonomic relationships of human parainfluenza viruses (HPIV). HPIVs were first discovered in the late 1950s when three different viruses were recovered from children with a lower respiratory disease which proved to be unique and easily separated from the myxoviruses (influenza virus) which closely resemble the parainfluenza virus. Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Parainfluenza Virus Infection in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2017-2028 for the following aspects:
• Prevalent Population of Parainfluenza Virus Infection
• Diagnosed Prevalent Population of Parainfluenza Virus Infection
• Prevalent Population of Parainfluenza Virus Infection based on the Serotypes
• Prevalent Population of Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients
According to a study conducted by H. Kelly et al. titled “Parainfluenza Viruses” the study threw light on the number of cases that come into the picture due to parainfluenza virus infections. It was found that between 500,000 and 800,000 LRI hospitalizations (in persons younger than 18 years) in the United States each year. Looking at the aspect of admitted cases for PIV according to serotype epidemiology each HPIV-1 resulted in an estimated 18,000– 3,50,000 US children younger than 5 years. For HPIV-2 as many as around 6000 children younger than 18 years may be hospitalized each year in the United States. About 60% of all HPIV-2 infections occur in children younger than 5 years, and although the peak incidence is between 1 and 2 years of age. For HPIV-3 scenario which is the most common amongst other serotypes, it was found that young infants (younger than 6 months) are particularly vulnerable to infection. Unlike the other HPIV, approximately 40% of HPIV-3 infections are in the first year of life. Bronchiolitis and pneumonia are the most common clinical presentations with HPIV-3. It is also worth noting that approximately 18,000 infants and children are hospitalized each year in the United States because of LRI caused by HPIV-3.
An another study conducted by J. Jerome et al. titled “Epidemiological, Molecular, and Clinical Features of Enterovirus Respiratory Infections in French Children between 1999 and 2005” concluded the Positive respiratory viral findings in the nasopharyngeal samples of 11,509 consecutive children attending one of the five referent pediatric emergency departments of the region Champagne Ardenne (France) from 1999 to 2005. Out of 11,509 children, 2444 (21%) were detected as positive for respiratory viral infections. The frequency of PIV Type-3 was found to be 2.4% amongst all positive respiratory viral infections.
Parainfluenza Virus Infection Drug Chapters
This segment of the Parainfluenza Virus Infection report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Parainfluenza Virus Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Parainfluenza Virus Infection & awareness of the disease. The overall dynamics of Parainfluenza Virus Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Ansun Biopharma will significantly increase the market during the forecast period (2019-2028).
Parainfluenza Virus Infection Market Outlook
The Parainfluenza Virus Infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The treatment landscape of Human Parainfluenza Virus (HPIV) comprises of very few pharmacotherapies. Currently, there are no antiviral agents with proven efficacy for Parainfluenza Virus Infection available in the market. The treatment and management of HPIV infection in healthy children and adults is mostly symptomatic. Parainfluenza Virus Infection is a common cause of significant mortality and morbidity in lung transplant recipients as well as in hematopoietic cell transplant recipients. The usual treatment and management for Human Parainfluenza Virus (HPIV) are focused on Symptomatic treatment, including preventive strategies. The current approaches to HPIV vaccines include intranasal administration of live attenuated strains, subunit strategies using the HN and F proteins, recombinant bovine/human viruses, and strains engineered using reverse genetics. In the United States, mortality is unusual and the cost of these viruses is seen mostly in health care utilization, hospitalization, lost productivity for parents, and, perhaps, long-term respiratory tract sequel in children. Ribavirin is Pharmacological drug used for the treatment of PIV infections, which has shown promising results in animal models and children with severe combined immunodeficiency. Ribavirin is a synthetic nucleoside analog which has broad-spectrum in vitro and in vivo activity against many RNA and DNA viruses. Corticosteroids are used as the primary treatment for croup and are known to be beneficial for mild-, moderate-to-severe croup. Corticosteroids are administered orally or given intramuscularly in the form of dexamethasone or prednisolone and both have been shown to be superior to inhaled therapy with budesonide. The drugs such as acetaminophen, ibuprofen are used commonly for the treatment of symptoms associated with PIV infection such as pain and fever. Other than these several other symptomatic relief options are also available like Heliox, nebulized epinephrine, etc.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Parainfluenza Virus Infection in G8 is expected to change from 2019-2028.
Parainfluenza Virus Infection Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Parainfluenza Virus Infection such as DAS-181 (Ansun Biopharma) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Parainfluenza Virus Infection market.
Parainfluenza Virus Infection Report Insights
• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Parainfluenza Virus Infection Report Key Strengths
• 10 Year Forecast
• G8 Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Parainfluenza Virus Infection Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Parainfluenza Virus Infection market
• Organize sales and marketing efforts by identifying the best opportunities for Parainfluenza Virus Infection market
• To understand the future market competition in the Parainfluenza Virus Infection market.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
